Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT07673614
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Chemotherapy-Induced Peripheral Neuropathy
  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Sham Intervention — PROCEDURE
    Undergo sham tDCS
  • Survey Administration — OTHER
    Ancillary studies
  • Transcranial Direct Current Stimulation — DEVICE
    Undergo tDCS

Study Details

This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.

Key Dates

Start date
Aug 1, 2026
Status verified
Jun 2026
Primary completion
Feb 29, 2028
Completion
Feb 29, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Arm I (active tDCS)
    Patients undergo tDCS to the sensorimotor cortex, using the Starstim-8™ system, for 20 minutes. One week later, patients cross-over to Arm II.
  • Sham Comparator: Arm II (sham tDCS)
    Patients undergo sham tDCS to the sensorimotor cortex, using the Starstim-8™ system, for 20 minutes. One week later, patients cross-over to Arm I.

Primary Outcome Measure

Vibration detection threshold [ Time Frame: at weeks 2 and 3 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Michigan Rogel Cancer CenterAnn ArborMichigan48109
Zoe Sowers
[email protected]
734-936-1208
Brendan L. McNeish (PRINCIPAL_INVESTIGATOR)

Find similar trials in Ann Arbor, MI

By research site
University of Michigan Rogel Cancer Center· Ann Arbor, MI

Related Studies